Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

Continue » Shares of Pfizer have been beaten down about 60% from their previous peak in 2021. The price is way down, but the company has raised its dividend payout every year since 2009.

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Pfizer is expected to post earnings of $0.57 per share for ...

But perhaps the greatest aspect of Robinhood's investment platform is the data it's willing to share. Robinhood's "100 Most ...

Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.